Chris Lu – CEO, Laekna Therapeutics, China
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Company info
Founded in December 2016, Laekna Therapeutics is a startup biotech company focusing on innovative drug discovery and development, we are dedicated to developing new targeted therapies to treat cancer and liver diseases.
Laekna has strong expertise in both small molecule and antibody discovery and development. Drs. Chris Lu and Yong Yue, and the rest of the leadership team have extensive R&D and management experience in global pharmaceutical companies, along with an exceptional track record of new drug approval and marketing. Laekna is a company full of energy and innovation. Our talented scientists strive to solve the biggest problems in healthcare and bring breakthrough medicines to patients.
Address: Floor 5, No. 987 Cailun Rd, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, China
Website: http://www.laeknatp.com/
Email: communication@laeknatp.com
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from…
What begins as frustration with the limits of academic research has developed into a story of entrepreneurship, scientific translation and sustainable biotech growth. Dr Thomas Schirrmann, Co-Founder and CEO of…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
The European Union is in the midst of the biggest shake-up of its pharmaceutical rulebook in a generation, racing to secure supply chains, speed up drug development, and keep Europe…
Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard…
Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical…
What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary…
Donghoon Lee outlines SK Biopharmaceuticals’ transformation into a global neuroscience player. He discusses the growth of its epilepsy profile, selective expansion into Parkinson’s disease and oncology, and acquisitions. Lee also…
Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for…
See our Cookie Privacy Policy Here
